CLUSTER filed Aug 12, 2026 at 16:05 ET
Twist Bioscience CEO Emily Leproust sold $14.2M in stock on Aug 10, 2026, following the company's strong Q3 earnings beat and raised guidance reported on Aug 3. The CEO's sale was part of a cashless exercise of 113,318 options at $26.66, with shares sold at $125.16 to cover taxes and realize gains. Director Robert Chess also sold $2.04M in a similar cashless exercise. Total insider selling of $18.14M represents 0.22% of the $8.2B market cap, which is modest in proportion. The cluster is dominated by option-exercise-related sales, not open-market liquidation of accumulated shares, reducing the bearish signal. The strong earnings beat and raised guidance provide a bullish fundamental backdrop that likely catalyzed these routine post-earnings sales.